Federica Galimberti has a solid multidisciplinary background acquired during her Master’s degree in Pharmaceutical Chemistry and Technology (University of Milan, 2016). During her 3-year PhD program in Experimental and Clinical Pharmacological Sciences at the Department of Pharmacological and Biomolecular Sciences (University of Milan, 2016-2019), she expanded her knowledge on pharmacoepidemiology and pharmaco-utilization, in the frame of prevention of cardiovascular diseases and associated risk factors. In details, she gained expertise in the design, conduction and monitoring of drug use and safety profile studies, and prescribing appropriateness studies, mainly through healthcare utilization databases analyses. The expertise in analysing data acquired during her PhD experience led her to spend a period at Cardiovascular Epidemiology Unit of University of Cambridge, where she enhanced her knowledge on genomic and pharmacogenomic topic related to the cardiovascular system, and experienced the conduction of studies based on the principles of Mendelian randomization to identify potential risk factors for cardiovascular disease, and to model “naturally randomized trials” that attempt to frame and answer clinical questions to fill evidence gaps when an actual clinical trial would be impractical or impossible to conduct. Currently, she is working as a researcher at IRCCS MultiMedica, Sesto San Giovanni (Milan).

After completing his training in Internal Medicine at Sapienza University of Rome, Dr Gallo obtained a PhD in Physiology, Physiopathology and Therapeutics at Sorbonne University. He works as a consulting physician at Pitié-Salpêtrière Sorbonne University Hospital. His clinical activity is focused on the management of genetic dyslipidaemias, as well as cardiovascular risk work-up of subjects with cardiovascular risk factors in primary prevention. His research interests include lipid metabolism, severe forms of genetic dyslipidaemias, especially familial hypercholesterolemia and familial hyperchylomicronaemia syndrome, residual risk in primary and secondary prevention, and imaging in atherosclerosis. His current projects are focused on vascular calcifications in familial hypercholesterolemia and their role in cardiovascular risk refining and prediction, retinal microvascular remodeling in cardiometabolic disease, and Lp(a) in secondary prevention cohorts. He is a member of the Young Fellows of EAS and French Atherosclerosis Society NSFA and has authored or co-authored more than 40 peer-reviewed publications.

Dr. Gaudet is affiliated to the Department of Medicine, Université de Montréal (UdeM). He is the scientific director of the UdeM Community Genetic Medicine Center and its Clinical Lipidology and Rare Lipid Disorders Unit. He is currently president and scientific director of ECOGENE-21, a non-for profit organization devoted to access to innovation in precision medicine. His main clinical and academic activities aim at investigating rare dyslipidemias and translating new knowledge issued from extreme phenotypes to more common forms of diseases. Over the years, he has coordinated more than 200 studies involving the development of screening tools, technologies or therapies for severe dyslipidemias or related disorders, in collaboration with biotechs, pharmas, or academic partners. He authored more than 300 scientific publications in peer-reviewed journals, including several tens in very highly rated Journals (NEJM, Lancet, Nature Medicine, Nature Genetics) as well as >500 scientific communications or book chapters.